Sponsored by Advanta Aesthetics;
Many aesthetic physicians are aware that live adipose derived cells (ADCs) are powerful regenerative tools that can be used in a wide range of aesthetic treatments such as skin rejuvenation and hair restoration.1 Up until now, the challenge with using ADCs has been the requirement that a patient undergo liposuction, but Creska by Advanta Aesthetics (Sheridan, Wyo.) is a revolutionary technology that is updating the way physicians use ADCs.
Creska is a non-expanded, FDA-compliant product with a number of potential applications. Classified as White Subcutaneous Skin Fat, Creska is intended for topical use as well as subcutaneous and intradermal injections.
Creska is designed to repair areas where skin and fat naturally exist. One study found that combining ADCs with laser skin resurfacing improved skin elasticity and hydration. Another found that combining ADCs with subcision treatment proved to be more effective in treating acne scars than using subcision alone.2, 3 In addition, a recent clinical trial found that combining platelet-rich plasma (PRP) treatments with ADCs reversed the effects of androgenetic alopecia (AGA) more efficiently than using PRP alone.4
According to Vince Liguori, lead consultant for Advanta Aesthetics, the difference between Creska and similar products is that Creska is a live cellular matrix, which they refer to as an adipose derived cellular allograft, or ADCA. “You could use this topically, intradermally and subcutaneously, which is extremely beneficial because many of the healing factors come from the subcutaneous part of the fat of the skin,” Mr. Liguori reported. “Patients get real regeneration in the dermis and hair and it can help patients with alopecia.” 
Currently, physicians are using Creska for breast augmentations, as a complementary or standalone treatment for facial rejuvenation, and to complement PRP hair treatments. “It can enhance a variety of regenerative procedures. For example, it is an ideal add on to dermal fillers,” explained Mr. Liguori. “Patients enjoy the short-term gratification from the filler and then long-term gratification with the results they continue to see, which, of course, increases patient satisfaction.” He added that he also sees Creska being used to complement Renuva (MTF Biologics) treatments, with Renuva adding volume and growth factors to the skin while Creska can speed cellular activity for a dramatic cellular boost.
“It is like the benefits of using cellular factors from liposuction without the cost, and you can do it multiple times per year and address multiple areas,” Mr. Liguori elaborated. Creska is a powerful homologous live allograft that works in skin and fat the way nature intended.
References:
1. Chen, S., He, Z. & Xu, J. Application of adipose-derived stem cells in photoaging: basic science and literature review. Stem Cell Res Ther 11, 491 (2020). https://doi. org/10.1186/s13287-020-01994-z
2. Zhou BR, Zhang T, Bin Jameel AA, Xu Y, Xu Y, Guo SL, Wang Y, Permatasari F, Luo D. The efficacy of conditioned media of adipose-derived stem cells combined with ablative carbon dioxide fractional resurfacing for atrophic acne scars and skin rejuvenation. J Cosmet Laser Ther. 2016 Jun;18(3):138-48. doi: 10.3109/14764172.2015.1114638. Epub 2016 Mar 8. PMID: 26735291.
26735291.
3. Rohaninasab, Masoumeh & Seifadini, Azadeh & Atefi, Najmolsadat & Sadeghzadeh-Bazargan, Afsaneh & Goodarzi, Azadeh & Hanifnia, Amir & Nouri, Maryam & Zare, Sona & Moradi, Sepideh & Dehghani, Abbas & Nilforoushzadeh, Mohammad Ali & Behrangi, Elham. (2022). Evaluating the effectiveness of Stromal-Vascular Fraction (SVF) cells along with subcision method in the treatment of acne scars: a double blind randomized controlled clinical trial study. Journal of Cosmetic Dermatology. 21. 10.1111/jocd.15375.
4. Butt G, Hussain I, Ahmad FJ, Choudhery MS. Stromal vascular fraction-enriched platelet-rich plasma therapy reverses the effects of androgenetic alopecia. J Cosmet Dermatol. 2020 May;19(5):1078-1085.doi: 10.1111/jocd.13149. Epub 2019 Sep 21. PMID: 31541565.
